Synthesis of Resveratrol Ester Derivatives Using Selective Enzymatic Hydrolysis. by Osei-Mensah, Marian
East Tennessee State University
Digital Commons @ East
Tennessee State University
Electronic Theses and Dissertations Student Works
12-2011
Synthesis of Resveratrol Ester Derivatives Using
Selective Enzymatic Hydrolysis.
Marian Osei-Mensah
East Tennessee State University
Follow this and additional works at: https://dc.etsu.edu/etd
Part of the Chemistry Commons
This Thesis - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State University. It
has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East Tennessee State
University. For more information, please contact digilib@etsu.edu.
Recommended Citation
Osei-Mensah, Marian, "Synthesis of Resveratrol Ester Derivatives Using Selective Enzymatic Hydrolysis." (2011). Electronic Theses and
Dissertations. Paper 1400. https://dc.etsu.edu/etd/1400
Synthesis of Resveratrol Ester Derivatives Using Selective Enzymatic Hydrolysis 
____________________________________ 
A thesis 
presented to 
the faculty of the Department of Chemistry 
East Tennessee State University 
 
In partial fulfillment 
of the requirements for the degree 
Master of Science in Chemistry 
_________________________________ 
by 
Marian Osei – Mensah 
December 2011 
__________________________________ 
Dr. Yu Lin Jiang, Ph. D, Chair 
Dr. Kady, Ph. D 
Dr. Peng Sun, Ph. D 
Keywords: Resveratrol, Polyphenols, Phytoalexin, Cancer, Bioavailability, Synthesis, Stilbene 
 
2 
 
ABSTRACT 
Synthesis of Resveratrol Ester Derivatives Using Selective Enzymatic Hydrolysis 
by 
Marian Osei – Mensah 
Resveratrol, a naturally derived stilbene, is an interesting compound mostly talked about recently 
because for its anti-cancer properties. Unfortunately it has some shortcomings due to its low 
bioavailability and low solubility in water. For this reason, my research is to overcome 
resveratrol’s drawbacks by improving its bioavailability and hydrophilicity. My research is 
focused on syntheses of novel derivatives of resveratrol such as 3, 5-di-O-isobutyroyl resveratrol 
and 3, 5-di-O-hexanoyl resveratrol using lipase catalyzed hydrolysis. Therefore, the tri-acylated 
resveratrols 3, 5, 4’-tri-O-isobutyroyl resveratrol and 3, 5,4’-tri-O-hexanoyl resveratrol were first 
synthesized. 
 
3,5,4’-tri-O-isobutyroyl resveratrol and 3,5,4’-tri-O-hexanoyl resveratrol were then hydrolyzed 
using lipase (C. Antarctica) to obtain the products 3,5-di-O-isobutyroyl resveratrol and 3,5-di-O-
hexanoyl resveratrol. The four compounds 3,5-di-O-isobutyroyl resveratrol, 3,5-di-O-hexanoyl 
resveratrol, 3,5,4’-tri-O-hexanoyl resveratrol, and  3,5-di-O-hexanoyl resveratrol were 
characterized by 
1
H NMR and 
13
C NMR. 
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CHAPTER 1 
INTRODUCTION 
Resveratrol (3, 5, 4’-trihydroxy-trans-stilbene) occurs in nature as a phytoalexin that is 
produced by several plants as a result of environmental pressure or pathogenic attack. It can be 
found in grapes, peanuts, mulberries, and blueberries.
1-3
 Considerable amounts of resveratrol can 
be found in wine as a result of its concentrated amount in grape skin.
4, 5
 Research has shown that 
red wine minimizes the risk of cardiovascular disease. 
6-9 
Resveratrol has various biological 
behaviors such as antioxidant,
10
 anti-inflammatory ,
11-13
 anti-ischemic,
14-16
 neuroprotective,
17,18
 
anti-aging,
19-21
 antiobesity,
22
 antiviral,
23
 cardioprotective,
24-26
 anticancer,
27
 and cancer 
chemopreventive effects.
1,28-30
 Resveratrol was found to hinder all the three stages of 
carcinogenesis: initiation, promotion, and progression.
1 
  Stilbene derivatives like resveratrol and all other naturally occurring phenolic 
antioxidants are compounds with two benzene rings connected to each other by ethylene. 
Currently, more interest has been directed to the development of possible approaches to 
transform and to improve the functional properties of natural antioxidants without changing the 
functionality responsible for the biological behavior. For instance, there has been an 
improvement of the hydrophobicity of antioxidant phenolic acids by esterifying the carboxylic 
acid moiety of the phenolic acid with a fatty alcohol by enzymatic and chemical methods.
31
 
Phenethyl alcohols have also been lipophilized by esterifying the alcoholic group with acid 
chlorides or acid anhydrides.
32
 Thus amphiphilic phenolic compounds were acquired and their 
function is to disseminate between the aqueous phase and the liphophilic phase and interact with 
an emulsifier at the interface. It has lately been accounted that these compounds are potentially 
remarkable for probable applications in nanotechnology.
33
 
12 
 
A number of acylated derivatives of resveratrol were found to be of  higher cell-growth 
prevention with regard to DU- 145 human prostate cancer cells than resveratrol itself.
34
 
However, a property of resveratrol that hinders the therapeutic applications is its limited 
bioavailability due to its quick metabolism in the liver that converts the resveratrol into less-
active 3-sulfate and 3-glucuronide derivatives.
35
 As a result, a serum half life of 8-14 min has 
been reported for resveratrol.
36
 An appropriate way to improve bioavailability is to have 
resveratrol derivatives that cannot be sulfated or glucuronated. In view of that, much attention is 
noted for the regioselective modification of the 3-OH’s.35 
Resveratrol is a symmetric molecule so the phenolic group at positions 3 and 5 are 
chemically equivalent and they have very similar reactivity with the phenolic group at position 4, 
so a special selectivity of enzymes 
37
 is being used for its regiospecific acylation 
34
 and 
oxidation.
38
 Regioselective acylation or deacylation catalyzed by lipases in organic solvents have 
especially been applied to polyphenolic compounds as a biocatalysed reaction to successfully 
answer many challenging standardized chemical reactions of regioselective derivatisation of 
polyhydroxylated compounds.
39-43
 
History and Discovery of Resveratrol 
Resveratrol as shown in (Figure 1) was first discovered in the 1940s in a variety of roots 
in both Japan and China and these roots were dried and then functioned as medicines. The dried 
root products were used to cure numerous skin infections such as athlete’s foot. 
13 
 
 
Figure 1. Structure of Resveratrol 
During 1976, resveratrol was found in the skin and seeds of grapes but not the flesh. As 
said by one researcher, the fresh grape skins contain 50-100 mg resveratrol per gram, and the 
concentration in wine varies from 0.2 mg/L to 7.7 mg/L. 
The French paradox gave rise to the research on the advantages of resveratrol because it 
is in relation to the drinking of wine in France and the minimal rate of cardiovascular problems 
among the French inhabitants. The outcome of resveratrol in red wines was as a result of this 
effect.
44
  
Biological Activity of Resveratrol 
Resveratrol has several major biological activities but here we discuss some of the most 
recent studies and applications in that field.  
Bioavailability is the rate at which a drug or a medication or other substance is absorbed 
or becomes accessible at the targeted position in the body,  and because living organisms 
response  depends on bioavailability the ability of intestines to take up resveratrol was 
demonstrated over 15 years ago by health benefits. This was acquired by orally administered 
resveratrol and it was first tested on rats and it prevented liver injury in rats fed peroxidized oil.
26
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Bertelli et al.
45
 showed that some of resveratrol in red wine (6.5 mg/L in cis and trans forms) was 
taken up by rats. Several tests with significant amount of 26 µg resveratrol or ingestion of 13 µg 
resveratrol on  daily basis over 15 days proved that the compound rapidly went into the blood 
stream and may possibly be identified in high concentrations in plasma and several organs. The 
same group of authors advanced their research in plasma kinetics and bioavailability of red wine 
resveratrol dispensed by an intragastric tube (28 µg per rat). The group explained 
pharmacokinetics by an open one- or two-compartment structure and found a considerable 
cardiac bioavailability and a strong affinity for the liver and the kidneys.
46
 In a different study, 
Bertelli et al.
47
 demonstrated that a moderate amount of resveratrol was pharmacologically 
effective in vitro as well as vivo. They therefore proposed that, continuing drinking wine for a 
long period of time allows the drinker to take in adequate amount of resveratrol which in turn 
explains the benefits of red wine on the human health.  
Anticancer 
Cancer is the unrestrained enlargement of irregular cells in the body. Cancer is the main 
cause of mortality in humans, killing more than 6 million people annually worldwide. It happens 
when a cell’s gene mutations make the cell incapable of correcting damaged DNA and unable to 
commit suicide.
48
 Carcinogens are a group of substances that are accountable for damaging 
DNA, advancing or supporting cancer. Some examples of carcinogens are tobacco, arsenic, 
asbestos, radiation such as gamma and x-rays, the sun, and compounds in car exhaust fumes.
48 
When our bodies are bare to these carcinogens, free radicals are produced and therefore make an 
effort to take electrons from several molecules in the body. The free radicals formed however 
destroy cells and have an effect on their capacity to perform normally.
48
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Age is also another risk for cancer. As we grow older, there is a rise in the cancer-causing 
mutations in our DNA. Again a number of viruses have been related to cancer such as human 
papillomavirus (a cause of cervical cancer), hepatitis B and C (causes of liver cancer), and 
Epstein-Barr virus (a cause of some childhood cancers). Human immunodeficiency virus (HIV) 
and anything for that matter that restrains or weakens the immune system inhibits the body’s 
capability to fight diseases and enhances the risk of developing cancer.
48 
Lastly cancer can be the 
outcome of genetic trend as a result of hereditary. Cancer can however be classified in five main 
groups.
48 
1. Carcinomas are represented by cells that cover up the internal and external parts of the 
body such as lung, breast, and colon cancer. 
2. Sarcomas are represented by cells that are found in the bone, cartilage, fat, connective 
tissue, muscle, and other supportive tissues. 
3. Lymphomas are cancers that start in the lymph nodes and immune system tissues. 
4. Leukemias are cancers that commence in the bone marrow and often build up in the 
bloodstream. 
5. Adenomas are cancers that happen in the thyroid, the pituitary gland, the adrenal gland, 
and other glandular tissues. 
The treatment of cancer is based on the type of cancer and the stage it has reached and can be put 
into six categories: surgery, radiotherapy, chemotherapy, immunotherapy, hormone therapy, or 
gene therapy.  
16 
 
Surgery  
It is recognized as the oldest treatment of cancer and it can be used to completely cure a 
patient by surgically removing the cancer from the body if the cancer has not metastasized. This 
is frequently observed in the getting rid of the prostate or a breast or testicle. However it is 
almost never possible to get rid of all the cancer cells after the disease has spread. Surgery 
possibly will as well be involved in aiding to regulate signs for instance bowel obstruction or 
spinal cord compression.
48
 
Radiotherapy  
This is a radiation treatment that damages cancer cells by concentrating high-energy rays on 
the cancer cells. It results in damaging the molecules that constitute the cancer cells and lead the 
cells to commit suicide. Radiation treatment makes use of high-energy gamma-rays that are 
emitted from metals, for example radium, or high-energy x-rays that are produced in a distinctive 
machine. Initial radiation treatments brought about serious consequences for the reason that the 
energy beams would destroy normal, healthy tissue; however, technologies have enhanced so 
that beams can be more precisely targeted. Radiation treatment functions as an individual 
treatment to minimize a tumor or to damage cancer cells (as well as those related to leukemia 
and lymphoma) and again used collectively in addition to several cancer treatments.
48
 
Chemotherapy  
Chemotherapy makes use of chemicals that meddle with the cell separation method – 
destroying protein or DNA – in order that cancer cells will commit suicide. The treatments aim 
at any fast dividing cells (not actually cancer cells), but healthy cells more often than not can 
17 
 
recuperate from any chemical-induced damage whereas cancer cells cannot. Chemotherapy is 
usually employed to cure cancer that has multiplied or metastasized because the medicines move 
all over the whole body. It is also an essential therapy for various kinds of leukemia and 
lymphoma. Chemotherapy treatment happens in phases, hence the body has longer period for 
healing between doses. Nevertheless, there are still familiar consequences such as hair loss, 
nausea, fatigue, and vomiting. Combination therapies usually comprise several forms of 
chemotherapy or chemotherapy combined with other treatment preferences.
48
 
Immunotherapy 
Immunotherapy seeks to make the body’s immune system battle the tumor. Local 
immunotherapy infuses medication into the affected part, for instance, to bring about 
inflammation that allows a tumor to contract. Systematic immunotherapy treats the entire body 
by dispensing a drug such as protein interferon alpha that can contract tumors. Moreover, 
immunotherapy can be regarded as non-specific if it enhances cancer fighting-capabilities by 
motivating the whole immune system, and it can be regarded as targeted if the treatment 
purposely informs the immune system to damage cancer cells. These therapies are comparatively 
new; however, scientists have had achievement with treatments that introduces antibodies into 
the body that prevent the growth of breast cancer cells. Another type of immunotherapy is bone 
marrow transplantation for the reason that the contributor’s immune cell will frequently attack 
the tumor that is available in the host.
48
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Hormone Therapy 
This is aimed to correct hormone formation in the body in order that cancer cells prevent 
developing or are destroyed entirely. Several cancer cells have been associated with various 
types of hormones, particularly breast and prostate cancer. Breast cancer hormone therapies 
usually concentrate on decreasing estrogen levels (a typical drug generally used is tamoxifen), 
whereas prostate cancer hormone therapies usually concentrate on lowering testosterone levels. 
Additionally, some leukemia and lymphoma situations can be cured with the hormone 
cortisone.
48
 
Gene Therapy  
Gene therapy’s objective is to replace damaged genes with ones that work to tackle the 
root cause of cancer, damage to DNA. For example, researchers are making an effort to replace 
the damaged gene that signals cells to stop dividing (the p53 gene) with a copy of working gene. 
Other gene-based therapies concentrate on further damaging cancer cell DNA to the point where 
the cell commits suicide. Gene therapy is an extremely new field and has so far not produced any 
success in treatments. 
  Three decades of research have revealed that cancer is easier to prevent than to treat. 
Food consumption provides various nutrients essential for life and good health as a whole. 
Certain daily diets that include specific nutrients may help decrease the danger of acquiring 
cancer. Chemoprevention is the prevention of cancer that is achieved by ingestion of chemical 
agents that lower the danger of carcinogenesis,
49 
and it is one of the shortest ways to lessen 
cancer. Some of  chemopreventive agents are nonsteriodal anti-inflammatory drugs (NSAIDs) 
19 
 
for instance aspirin, indomethacin, piroxicam, and sulindac all of which inhibit cyclooxygenase 
(COX).
50 
COX acts as a catalyst in the conversion of arachidonic acid to pro-inflammatory 
substances such as prostaglandins that can promote tumor cell growth and reduce the immune 
system.
51
  Moreover, COX can trigger carcinogens that destroy genetic material.
52
 
The discovery of resveratrol was as a result of the search for new chemopreventive 
agents. On the basis of bioassay-guided fractionation of plant extract gathered in Peru, 
resveratrol was known to be a strong COX inhibitor.
1
 The technique of the chemical 
carcinogenesis can be grouped into three main stages and the chemopreventive agents have been 
classified along with the stage they inhibit.
53
 The stages resveratrol inhibits are tumor initiation, 
promotion, and progression. 
Anti-Diabetic Effects 
Researchers have revealed that resveratrol has hypoglycemic and hypolipidemic effects 
in both streptozotocin (STZ)-induced diabetes and STZ-nicotinamide-induced diabetes in rats. 
Resveratrol improves the frequent diabetes symptoms such as polydipsia, polyphagia, and body 
weight loss.
54
Another research performed by Sirtris Pharmaceutical Inc. demonstrated that in 
human clinical trials, resveratrol reduced the blood sugar levels in both Phase Ib and Phase IIa.
55
   
Anti-Viral Effects 
Studies demonstrate that resveratrol inhibits herpes simplex virus (HSV) types 1 and 2 
replication by blocking of an early stage in the virus replication cycle. Research in mice in vivo 
reveals that resveratrol inhibits or lowers HSV replication in the vagina and as a result reduces 
extra-vaginal disease. It was evident that animals whose skins were healed with resveratrol 
20 
 
demonstrated no dermal contamination or toxicity such as scaling, erythema, crushing, 
lichenification, or excoriation.
56
 Research also reveals that resveratrol inhibits varicella-zoster 
virus, specific influenza virus, respiratory viruses, and human cytomegalovirus. Moreover, 
resveratrol works with and improves the anti-HIV-activity of some anti-HIV drugs.
57 
Mechanism of Action
 
Resveratrol has numerous beneficial effects, but the mechanism of action is not yet clear, 
although several direct targets have been discovered for it. Resveratrol exhibits antioxidant 
properties by the addition of exogenous red wine dilutions in aqueous environment to isolated 
LDL in a buffer solution.
58
 Resveratrol additionally exhibits anti-cyclooxygenase activity by 
inhibiting COX on the basis of bioassay-guided fractionation.
1
 Once more, resveratrol displays a 
modulating result on lipid and lipoprotein metabolism by the blockage of lipid assimilation and 
the speeding up of lipid consumption in muscles.
59 
  Resveratrol again blocks ribonucleotide reductase, the enzyme that supplies proliferating 
cells with deoxyribonucleotides necessary for DNA synthesis at its initial S-phase of the cell 
cycle,
60
 and DNA polymerases and hinders the mitogen-activated protein kinase and protein 
kinase C alleys.
61
 Lastly, resveratrol is a powerful activator of sirtuin activity and as a result 
imitates the health benefits of caloric limitations.
62
Sirturns are a preserved family of  NAD+-
dependant deacetylases and resveratrol, as a tiny molecule activator of  sirtuin lengthens yeast 
and other higher organisms existence on earth.  
Derivatives of Resveratrol 
There are several naturally occurring stilbene-like compounds that are similar to 
resveratrol and also found in food. These compounds are referred to as derivatives of resveratrol 
21 
 
and an insight of the structure-activity creates new possibilities for drug discovery and other 
applications. For instance, a number of acylated derivatives have revealed higher cell-growth 
prevention with regard to DU- 145 human prostate cancer cells than resveratrol itself 
34 
due to  
resveratrol’s limited bioavailability. 
Methoxylated Resveratrol Derivatives 
Analysis of structure-activity discovered that the substitution of hydroxyl groups of 
resveratrol with methoxy groups considerably improve its cytotoxic activity.
63
 Therefore, some 
researchers have done a lot of studies on series of methoxylated analogs of resveratrol with the 
aim of increasing the antitumor activity of resveratrol. Several other stilbenes besides resveratrol, 
that are similar in structure to resveratrol, occur naturally in food. An example of this is 
pterostilbene (Figure 2), a dimethylated analog of resveratrol is found in blueberries that has 
been studied broadly. The substitution of hydroxyl with methoxy groups increases the 
lipophilicity of pterostilbene over resveratrol, resulting in better bioavailability.
64
 
Examples of methoxylated resveratrol derivatives shown in (Figure 2) include;  
 
Pterostilbene  Trimethoxystilbene             Tetramethoxystilbene Pentamethoxystilbene 
  Figure 2. Structure of selected methoxylated derivatives of resveratrol 
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Hydroxylated Derivative of Resveratrol 
A common example of a hydroxylated derivative of resveratrol is Piceatannol (3, 4, 3’, 5’-
tetrahydroxystilbene Figure. 3), the metabolite of resveratrol found in red wine. LMP2A, a viral 
protein-tyrosinekinase linked to leukemia, Non-Hodgkin’s lymphoma, and other diseases related 
to Epstein-Barr virus (EBV) also called human herpes virus4 (HHV4), was discovered to be 
blocked by piceatannol in vivo. These introductory studies on piceatannol have attracted a great 
deal of research interest as a potential anti-cancer and anti-EBV drug.
65
  
Examples of hydroxylated derivatives of resveratrol shown in (Figure 3) are; 
                             
Hydroxystilbene                         Dihydroxystilbene               Tetrahydroxystilbene 
Figure 3. Structure of selected hydroxylated derivatives of resveratrol continued on next page 
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Pentahydroxystilbene                          Hexahydroxystilbene                   Piceatannol 
Figure 3. Structure of selected hydroxylated derivatives of resveratrol 
Other Resveratrol Derivatives 
The derivatives of other resveratrol as shown in (Figure 4) include; 
                           
 Resveratrol triacetate                         Digalloylresveratrol 
     Figure 4. Structure of other derivatives of Resveratrol 
24 
 
Adverse Effects and Unknowns of Resveratrol 
Until now the long-term effects of using resveratrol is not known.
66 
Although the health 
benefits of resveratrol are remarkable, research has come out with a concept that it may promote 
the development of human breast cancer cells, probably for the reason that the chemical structure 
of resveratrol and phytoestrogen are alike.
67
 On the other hand, that research have shown that  
ingestion of resveratrol reduces the risk of breast cancer in mice.
68 
 Other research also found that 
resveratrol slows down the growth of blood vessels that hold back tumors, although it delays 
healing.
69
 From the indication that resveratrol may be estrogen detrimental, certain sellers of 
resveratrol suggested that the product may meddle with oral contraceptives and that pregnant 
women or women looking forward to be pregnant must not take the compound,  yet a different 
group also suggested that children or teenagers under 18 should not take resveratrol because 
research have not shown its influence on human development. A small research work showed 
that one dosage equal to 5 g of trans-resveratrol has no severe bad consequences in healthy 
volunteers.
70
  
Lipase Protection of Resveratrol Derivatives 
Selectivity in the modification of many functional groups on one compound is 
particularly an important objective in organic synthesis and because of that a lot of attention is 
paid to research of new selective methods. It has been discovered that lipases are capable of 
functioning in organic solvents, so this brings about a wide application of these biocatalysts in 
organic synthesis.
71-72
 Lipases are enzymes that have high molecular identification potentials and 
as a result can be used in the selective modification of polyhydroxylated aromatic and aliphatic 
substrates. Research shows that C. Antarctica is highly specific for the phenolic group at 4’-OH, 
34
 because it is less sterically hindered than the 3-OH.
73
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Functional Group Activity 
The OH group at position 4’ (para) on resveratrol is more stable than the OH groups at 
position 3 and 5 (meta) because the para position has more resonance structures than the meta. 
This is shown in Scheme 1 and Scheme 2. 
 
 
                  
   
 
Scheme 1. The resonance structures of resveratrol involving abstraction of a proton from the 
para-hydroxyl group 
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Scheme 2. The resonance structures of resveratrol involving abstraction of a proton from the 
meta-hydroxyl group 
Chemical Synthesis of Resveratrol 
There are various reactions used to synthesize resveratrol, but the reaction mainly used is 
the decarbonylative Heck reaction. This reaction involves the chemical reaction of an 
unsaturated halide with an alkene and a strong base in the presence of a palladium catalyst to 
form a substituted alkene. The resveratrol acetate formed is then reacted with sodium hydroxide 
in THF followed by washing with brine and water to produce resveratrol. The Heck’s reaction is 
outlined in Scheme 3. 
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Scheme 3. Synthesis of resveratrol using Heck’s reaction 
Apart from Heck’s reaction, Perkin reaction is also another commonly used organic reaction. 
The Perkin reaction is carried out by the aldol condensation of aromatic aldehydes and acids in 
the presence of an alkali salt of the acid. This reaction is believed to involve fewer steps with 
good percent yield (~70%).  The Perkin’s reaction is outlined in Scheme 4. 
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 Scheme 4. The Perkins Reaction 
Wittig’s reaction can also be used to synthesize resveratrol; however, it the produces a 
mixture of olefin isomers. 
Purpose of Research 
The main aim of this research is to synthesize resveratrol derivatives, 3,5-di-O-
isobutyroyl resveratrol and 3,5-Di-O-hexanoyl resveratrol using lipase catalyzed hydrolysis. This 
research is to modify resveratrol to improve its low bioavailability and solubility in water.  
Proposed Synthetic Pathway for Synthesis of 3,5,4’-tri-O-isobutyroyl Resveratrol 
The synthesis of 3,5,4’-tri-O-isobutyroyl resveratrol was an esterification synthesis of 
resveratrol as outlined in Scheme 5 and its mechanism is outlined in Scheme 6. 
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    Scheme 5. Synthesis of 3,5,4’-tri-O-isobutyroyl resveratrol ( Esterification)  
 
 
Scheme 6. Mechanism of 3,5,4’-tri-O-isobutyroyl synthesis resveratrol using esterification of 
reseveratrol  
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Proposed Synthetic Pathway for Synthesis of Hexanoyl Chloride 
Compound 3 was synthesized by the reaction between hexanoic acid and thionyl chloride 
as shown in scheme 7. Acyl chlorides (hexanoyl chloride) are generally prepared by replacing 
the equivalent hydroxy substituents with chlorides. In this reaction, the sulfur dioxide (SO2) and 
hydrogen chloride (HCl) generated are both gases that can evaporate from the reaction vessel. 
Excess thionyl chloride can also evaporate because the boiling point is 79
o
C. 
 
Scheme 7. Synthetic pathway for hexanoyl chloride 
Proposed Synthetic Pathway for Synthesis of 3,5,4’-tri-O-hexanoyl Resveratrol 
The synthesis of 3,5,4’-tri-O-hexanoyl resveratrol was an esterification synthesis of 
resveratrol as outlined in Scheme 8. 
Scheme 8. Synthesis of 3,5,4’-tri-O-hexanoyl resveratrol (Esterification) 
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Proposed Synthetic Pathway for Synthesis of 3,5-di-O-isobutyroyl Resveratrol and 3,5-di-O-
hexanoyl Reseveratrol 
Lipase (C. Antarctica) used in this reaction is highly specific for the phenolic group at 
position 4’ because it is less sterically hindered, Scheme 9. The mechanism of this reaction is 
outlined in Scheme 10. 
 
Scheme 9. Enzymatic synthesis of 3,5-di-O-isobutyroyl resveratrol and 3,5-di-O-hexanoyl 
resveratrol 
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Scheme10. Mechanism of 3,5-di-O-isobutyroyl resveratrol and 3,5-di-O-hexanoyl resveratrol 
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CHAPTER 2 
RESULTS AND DISCUSSION 
Synthesis of 3,5,4’-tri-O-isobutyroyl Resveratrol, 2 
 
A high yield of 90% of compound 2 was obtained as white crystals after purification of 
the crude product using column chromatography. The RF value for the tri-ester was 0.67. The 
triethylamine acts as a nucleophile and attacks the carbonyl carbon of the isobutyroyl chloride. 
The carbonyl carbon then forms a bond with the 4’ oxygen resveratrol after the chloride ion 
picks the phenol proton. The reaction continued until the phenol positions at 3 and 5 all acylated 
as shown in scheme 5. 
Synthesis of Hexanoyl Chloride, 3 
 
3 
Pure compound 3 was obtained as a slightly yellow liquid in 90% by reacting hexanoic 
acid with thionyl chloride in dichloromethane. 
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Synthesis of 3,5,4’-tri-O-hexanoyl Resveratrol, 4 
 
4 
A high yield of 95% of compound 4 was obtained as a yellow liquid after purification of 
the crude product using column chromatography. The RF value for the tri-ester was 0.66. The 
reason for compound 4 being a liquid is because of the long straight carbon chains on the 
stilbene. This makes the compound have a large surface area that can accommodate more 
interactions resulting in higher boiling point because of higher molecular weight. 
Synthesis of 3,5-di-O-isobutyroyl Resveratrol, 5 
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Compound 5 was obtained as white crystals with a moderate yield of 25 percent. The RF 
value for the di-ester was 0.56. The n-butyl alcohol used in the reaction acted as a nucleophile. 
The tert-butyl methyl ether was used as a solvent to dissolve the tri-ester. The enzyme reaction 
was difficult and the low yield produced was due to very difficult separation. The 30 minutes 
reaction time which was reported could not work for my compound. Several other reaction times 
were tried using that same method and it became successful when the reaction was run for 24 
hours. The reason for the previous unproductive method was because of the large group at the 
4’position which needed much time for the reaction to go to completion. Table 1 gives the 
summary of the reaction results. 
Table 1. Summary of Reaction Results 
Resveratrol Tri-ester 
Mass (mg) 
Reaction Time @ 
40
o
C , 280 rpm 
Resveratrol Di-ester 
Yield (%) 
Resveratrol Tri-ester 
Recovery (%) 
100 mg 30 min None 100 
100 mg 1hr None 100 
100 mg 3hrs None 100 
100 mg 9hrs None 100 
100 mg 12hrs < 1 98 
100 mg 24 hrs 25 75 
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Synthesis of 3,5-di-O-hexanoyl Resveratrol, 6 
 
6 
Compound 6 was obtained as white crystals after purification of the crude product using column 
chromatography with a moderate yield of 41%. The RF value for the di-ester was 0.49. 
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Conclusion 
The objective of this research was fulfilled. The compounds, 3,5,4’-tri-O-isobutyroyl 
resveratrol and 3,5,4’-tri-O-hexanoyl resveratrol have been synthesized with pure yield of 90% 
and 95%, respectively. Moreover, 3,5-di-O-isobutyryl resveratrol and 3,5-di-O-hexanoyl 
resveratrol, that was my main research objective, have also been successfully synthesized with 
pure yields of 25% and 41%, respectively. All the compounds, 3,5,4’-tri-O-isobutyroyl 
resveratrol, 3,5,4’-tri-O-hexanoyl resveratrol, 3,5-di-O-isobutyroyl resveratrol, and 3,5-di-O-
hexanoyl resveratrol are new, publishable, and may be evaluated in biological systems. 
 The main synthetic routes used in my research were chemical and enzymatic 
esterification of phenolic compounds. The disadvantage with the chemical synthesis is that a lot 
of side reactions occur making it difficult to separate because it is relatively unselective. With the 
enzymatic synthesis, because it is selective it has an advantage over the chemical synthesis in 
that there is a minimization of side reactions making the purification steps very few. The only 
problem with the enzymatic synthesis is that the yield is not as high as that of the chemical 
synthesis.  
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CHAPTER 3 
EXPERIMENTAL 
General Methods 
Resveratrol and other commercial reagents were used without extra purification and they 
were acquired from sigma (St. Louis, MO, USA). The data of all proton (
1
H) and (
13
C) NMR 
spectra were taken from JEOL-NMR Eclipse spectrometer operating at 400 MHz and 100 MHz 
for proton and carbon nuclei respectively. The solvents used for the spectra were CD3COCD3, 
CD3OD, and CDCl3 unless otherwise stated. Chemical shifts were recorded as delta values in 
parts per million (ppm) relative to TMS. From the spectra, the multiplicity of the signals was 
documented as s (singlet), d (doublet), t (triplet), h (hextet), hept (heptet), and m (multiplet). 
Silica gel and suitable solvents were used in carrying out the column chromatography. Thin layer 
chromatography (TLC) was done with silica gel plate using suitable solvent mixtures and viewed 
under UV Fluorescent indicator. Melting points for the crystals were recorded using Cambridge 
MEL-TEMP instrument. All weighing was performed on Mettler PJ360 Delta Range scale unless 
otherwise stated.  
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Experimental Procedures 
Synthesis of 3,5,4’-tri-O-isobutyroyl Resveratrol 
  
Resveratrol (1.04 g, 4.56 mmol) was dissolved in acetone (35 mL) acting as the solvent, 
and isobutyroyl chloride (1.46 g, 13.68 mmol ) and triethylamine ( 1.38 g, 13.68 mmol) were 
added to it and stirred in a 50-mL round bottom flask for 12 hours. The solution was then 
acidified (≤5) with hydrochloric acid (2N). The crude product was extracted in the organic layer 
by means of ethyl acetate (2×35 mL). The excess hydrochloric acid was removed by washing 
with sodium hydrocarbonate (35 mL). The product was dried by means of magnesium sulfate 
followed by gravity filtration. The crude product was purified again using column 
chromatography. Melting point of pure compound was 85
o
C – 87oC.                                                                           
1
HNMR (CD3OD/CD3COCD3, 400MHZ, ppm) δ1.27 (d1, 18H, CH3); δ 2.84 (m, 3H, CH); δ 6.71 
(dd1, 1H,  Ar-H); δ 6.78 (d1, 1H, CH=C); δ 7.26 (dd1, 2H,  Ar-H); δ 7.00 (d1, 1H, CH=C); δ 7.12 
(ddd1, 2H, Ar-H); δ  7.41 (ddd1, 2H, Ar-H) 
13
CNMR (CD3OCD3,100 MHz, ppm) δ 18.32, 34.01, 
114.87, 116.99, 122.15, 127.06, 127.70, 129.60, 134.60, 139.74, 151.07, 151.98, 174.67, 174.89 
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Synthesis of Hexanoyl Chloride 
 
Hexanoic acid (4 mL, 32 mmol) was put in a 25-mL round bottomed flask in addition 
with 5 mL dichloromethane. Thionyl chloride (4.64mL, 64 mmol) was added drop wise and 
stirred for an hour for the gases to escape. The mixture was put in an oil bath at 50
o
C for 
additional hour to allow all the gas to evaporate. The mixture was then distilled to first collect the 
dichloromethane and then excess thionyl chloride (boiling point, 79
o
C) and lastly hexanoyl 
chloride (boiling point, 151-153
o
C). A dark brown liquid residue was left behind. 
1
HNMR 
(400MHz, CDCl3, ppm) δ 0.81 (t1, 3H, CH3); δ 1.23 (h, 2H, CH2); δ 1.23 (tt1, 2H, CH2); δ 1.59 
(tt1, 2H, CH2); δ 2.77 (t1, 2H, CH2) 
Synthesis of 3,5,4’-tri-O-hexanoyl Resveratrol 
 
Resveratrol (1.00 g, 4.386 mmol) was dissolved in acetone (33 mL) and hexanoyl 
chloride (1.771 g, 13.158 mmol ) and triethylamine ( 1.331 g, 13.158 mmol) were added and 
stirred in a 50-mL round bottom flask for 12 hours. The solution was then acidified with 
41 
 
hydrochloric acid (2N). The crude product was extracted with ethyl acetate (2×33 mL). The 
excess hydrochloric acid was removed by washing the organic layer with saturated sodium 
hydrocarbonate (33 mL) and drying over magnesium sulfate followed by gravity filtration. The 
crude product was obtained by evaporation of solvent and was purified using column 
chromatography. 
1
HNMR (CD3COCD3, 400MHz, ppm) δ0.90 (t1, 9H, CH3); δ 1.37 (m, 6H, 
CH2); δ 1.37 (tt1, 6H, CH2); δ 1.71 (tt1, 6H, CH2); δ 2.57 (t1, 6H, CH2); δ 6.84 (t1, 1H,  Ar-H); δ 
7.23 (d1, 1H, CH=C); δ 7.14 (dd1, 2H,  Ar-H); δ 7.24 (d1, 1H, CH=C); δ 7.25 (ddd1, 2H, Ar-H); δ  
7.65 (ddd1, 2H, Ar-H) 
13
CNMR (CDCl3,100 MHz, ppm) δ 13.61, 22.01, 25.00, 31.50, 34.10, 
115.14, 117.22, 122.40, 127.27, 127.90, 129.78, 134.77, 139.92, 151.17, 152.06, 171.60, 171.79 
Synthesis of 3,5-di-O-isobutyroyl Resveratrol 
 
3,5,4’-tri-O-isobutyroyl resveratrol (100 mg, 0.023 µmol) was dissolved in t-butyl methyl 
ether (5 mL, 42 mmol) in 25-mL round bottom flask. A mixture containing C. Antarctica (100 
mg) and n-butyl alcohol (0.4 mL) was added to the round bottom flask. The mixture was stirred 
by the help of a rotovap (40
o
C, 280 rpm) for 24 hrs. After 24 hrs, the enzyme was filtered and the 
filtrated was left to evaporate leaving behind the crude product. The crude product was purified 
by the use of column chromatography. Melting point of pure product was 142
o
C – 145oC. 
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1
HNMR (CD3OD 400MHZ, ppm) δ1.29 (d1, 12H, CH3); δ 2.81 (m, 2H, CH); δ 6.71 (dd1, 1H,  
Ar-H); δ 6.78 (ddd1, 2H,  Ar-H); δ 7.00 (ddd1, 1H,  Ar-H); δ 7.10 (dd1, 2H,  Ar-H); δ 7.11 (d1, 
1H, C=CH); δ  7.12 (d1, 1H, C=CH ) δ 7.41 (ddd1, 1H,  Ar-H) 
13
CNMR (CD3OD,100 MHz, 
ppm) δ 17.93, 33.98, 113.50, 115.23, 116.23, 123.53, 127.97, 128.49, 130.49, 151.75, 158.06, 
175.58 
Synthesis of 3,5-di-O-hexanoyl Resveratrol                                                                   
 
 
3,5,4’-tri-O-hexanoyl resveratrol (0.743 g, 1.423 mmol) was put in a 100-mL round 
bottom flask together with “t”-butyl methyl ether (37.2 mL, 0.313 mol). A mixture containing C. 
Antarctica (0.743 g) and n-butyl alcohol (3.0 mL) was added to the round bottom flask. The 
mixture was stirred by the help of a rotovap (40
o
C, 280 rpm) for 24 hrs. After 24 hrs, the enzyme 
was filtered and the filtrated was left to evaporate leaving behind the crude product. The crude 
product was purified by the use of column chromatography. Melting point of pure product was 
98
o
C – 100oC. 1HNMR (CD3COCD3, 400MHZ, ppm) δ0.90 (t1, 6H, CH3); δ 1.37 (m, 4H, CH2); 
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δ 1.37 (tt1, 4H, CH2); δ 1.71 (tt1, 4H, CH2); δ 2.59 (t1, 4H, CH2); δ 6.80 (dd1, 1H,  Ar-H); δ 7.06 
(d1, 1H, CH=C); δ 6.86 (dd1, 2H,  Ar-H); δ 7.19 (d1, 1H, CH=C); δ 7.46 (ddd1, 2H, Ar-H); δ  
7.48 (ddd1, 2H, Ar-H); δ 8.59 (s, 1H, OH) 
13
CNMR (CDCl3,100 MHz, ppm) δ 13.42, 22.00, 
24.50, 31.00, 33.50, 114.28, 115.59, 115.68, 116.61, 123.96, 128.30, 128.62, 130.46, 140.33, 
151.84, 157.83, 171.41 
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